Cipla (CIPLA) Aperçu de l'action
Cipla Limited et ses filiales fabriquent, développent, vendent et distribuent des produits pharmaceutiques en Inde, aux États-Unis, en Afrique du Sud et dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 3/6 |
| Croissance future | 1/6 |
| Performances passées | 2/6 |
| Santé financière | 6/6 |
| Dividendes | 4/6 |
Récompenses
Analyse des risques
CIPLA Community Fair Values
Create NarrativeSee what 44 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cipla Limited Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | ₹1,418.20 |
| Plus haut sur 52 semaines | ₹1,673.00 |
| Plus bas sur 52 semaines | ₹1,165.70 |
| Bêta | 0.093 |
| Variation sur 1 mois | 7.67% |
| Variation sur 3 mois | 4.43% |
| Variation sur 1 an | -3.43% |
| Variation sur 3 ans | 48.81% |
| Variation sur 5 ans | 48.55% |
| Évolution depuis l'introduction en bourse | 43,848.85% |
Nouvelles et mises à jour récentes
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...
CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.Recent updates
Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Here's Why Cipla (NSE:CIPLA) Can Manage Its Debt Responsibly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Rendement pour les actionnaires
| CIPLA | IN Pharmaceuticals | IN Marché | |
|---|---|---|---|
| 7D | 1.3% | 0.004% | 2.0% |
| 1Y | -3.4% | 10.7% | 0.4% |
Rendement vs Industrie: CIPLA a sous-performé le secteur Indian Pharmaceuticals qui a rapporté 10.7 % au cours de l'année écoulée.
Rendement vs marché: CIPLA a sous-performé le marché Indian qui a rapporté 0.4 % au cours de l'année écoulée.
Volatilité des prix
| CIPLA volatility | |
|---|---|
| CIPLA Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.2% |
| 10% least volatile stocks in IN Market | 4.8% |
Cours de l'action stable: CIPLA n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché Indian.
Volatilité au fil du temps: La volatilité hebdomadaire de CIPLA ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 1935 | 30,313 | Achin Gupta | www.cipla.com |
Cipla Limited, avec ses filiales, fabrique, développe, vend et distribue des produits pharmaceutiques en Inde, aux États-Unis, en Afrique du Sud et dans le monde entier. L'entreprise opère par le biais des segments Pharmaceuticals et New Ventures. Elle propose des médicaments génériques et des médicaments génériques de marque, des vaccins, des ingrédients pharmaceutiques actifs et des formulations pour divers domaines thérapeutiques, tels que l'infarctus, l'angine, les maladies cardiaques, les maladies pulmonaires, l'insuffisance rénale, la maladie d'Alzheimer, l'hypertension, l'arythmie, les anomalies lipidiques et le diabète, l'obésité, le système nerveux central, le VIH/SIDA, les maladies respiratoires, l'asthme, l'urologie, l'oncologie, le cardio-métabolisme, la santé infantile, les maladies infectieuses et les soins intensifs, l'hépatite, la santé des femmes, l'ophtalmologie et la neuropsychiatrie.
Cipla Limited Résumé des fondamentaux
| CIPLA statistiques fondamentales | |
|---|---|
| Capitalisation boursière | ₹1.15t |
| Bénéfices(TTM) | ₹38.79b |
| Recettes(TTM) | ₹277.12b |
Le site CIPLA est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CIPLA compte de résultat (TTM) | |
|---|---|
| Recettes | ₹277.12b |
| Coût des recettes | ₹95.49b |
| Marge brute | ₹181.63b |
| Autres dépenses | ₹142.83b |
| Les revenus | ₹38.79b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | 48.02 |
| Marge brute | 65.54% |
| Marge bénéficiaire nette | 14.00% |
| Ratio dettes/capitaux propres | 0.7% |
Quelles ont été les performances à long terme de CIPLA?
Voir les performances historiques et les comparaisonsDividendes
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/27 21:46 |
| Cours de l'action en fin de journée | 2026/05/27 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2026/03/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cipla Limited est couverte par 56 analystes. 35 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |